Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients

Figure 3

Serum IL-5 and IFN-γ levels reflect pseudoprogression in 2 metastatic NSCLC patients during anti-PD-1 mAb treatment. Serum IL-5 and IFN-γ levels were tested at baseline, at pseudoprogression diagnosis (first in tumor lesion size) and at subsequent imaging evaluations that fulfilled criteria of partial response (PR). Although imaging-evaluated increases in the lesion size during pseudoprogression, serum IL-5 and IFN-γ levels decreased and remained below the baseline levels.